Transactions

Stephen Saad’s address on the occasion of President Cyril Ramaphosa’s visit at our Sterile Facility in the Eastern Cape at which time he announced the agreement reached with Johnson & Johnson to supply 250 million covid-19 vaccines to Africa, with 30 million being for South Africa

Gqeberha, South Africa – Aspen, a global multinational specialty pharmaceutical company, earlier today hosted President Cyril Ramaphosa and an accompanying government delegation at its flagship manufacturing site in the Eastern Cape. Aspen has invested in excess of R3.0 billion at this sterile manufacturing site, the single largest investment in the pharmaceutical industry in South Africa. The new sterile facility contains high-technology, state-of-the-art pharmaceutical equipment and systems that will be used to manufacture advanced sterile medicines, including vaccines.   These investments at the Gqeberha manufacturing site, which has been a cornerstone of both local ARV and MDR TB manufacture, demonstrate Aspen’s ongoing and enduring commitment to South Africa and the continent. With roots firmly embedded in African soil, a continent which carries a disproportionately high disease burden, the investment in advanced pharmaceutical technology enables Aspen to continue to contribute to improved access to treatment, respond to public health emergencies and to create significant economic, export and job creation opportunities. This facility will allow Aspen to manufacture multiple and complex sterile products, such as vaccines and Aspen’s global anaesthetics. It will also ensure quality and security of both domestic and international supply.  As South Africa and the world grapples with the management of the COVID pandemic, this strategic investment will materially contribute to the management of this pandemic. Through the collaboration announced between Aspen and Johnson & Johnson, Aspen is the only manufacturing site on the African continent and in the southern hemisphere selected by Johnson & Johnson to compound, fill, finish and package the Janssen (a Johnson & Johnson company) COVID-19 vaccine. Aspen and Johnson & Johnson’s commitment to Africa is further underpinned by continued collaboration to enhance the amount of vaccines produced at this facility, with most of the production serving the needs of Africans. We are very proud and grateful to have the opportunity to partner with one of the world’s largest and most technologically advanced healthcare companies who has committed to ensuring equitable access to COVID-19 vaccines. This has been demonstrated through their actions and was fundamental in our considerations of which company to partner. The Aspen and Johnson & Johnson project teams responsible for the technical transfer process at the new sterile facility, worked tireless ensuring collaboration in keeping to the ambitious goals and beating timelines. During this time, the Aspen project team have strengthened their technical competencies, complementing the capabilities of these highly skilled Aspen employees and enhancing a knowledge base in South Africa that will contribute to further solving future public challenges. Most of the vaccines manufactured at this Aspen’s new sterile facility in 2021 will be supplied to South Africa and the member states of the African Union.  The South African government agreement with Johnson & Johnson, is to deliver more than 30 million doses of the Janssen COVID-19 vaccine to South Africans, with the first deliveries being made in April 2021. The African Union is expected to receive over 400 million doses. Addressing delegates at Aspen’s sterile facility in Gqeberha, H.E. President Cyril Ramaphosa said, “We are here to see how we can save lives. I am pleased to inform you that Johnson & Johnson has agreed to make 250 million vaccines available to Africa with 30 million for South Africans.  Coming here to this facility in Gqeberha has been an honour. Aspen belongs to us as South Africans and it is making life saving vaccines and we as South Africans must be in pole position to receive these vaccines and for them to be made available to the continent immediately. We are pleased of what we have seen here and the commitment of Aspen’s people. This world class facility is in another league and I congratulate Aspen on this facility to manufacture vaccines for our country and for our continent. I would also like to congratulate Aspen on living up to their promise of investing more than R3 billion in our country.”  Stephen Saad, Aspen Group Chief Executive said, “This is a watershed moment for Aspen as we continue to implement our strategic vision of delivering quality, affordable medicines using high-technology pharmaceutical equipment, contributing to improved health outcomes. This vision has come with much sacrifice and perseverance however we have been rewarded through the endorsement of the relevance of our product portfolio and capital investments at our manufacturing facilities. Our sterile capacity is a big step to ensuring that Africa has both the capacity and capabilities to reduce its reliance on other countries in addressing its healthcare priorities. The manufacture of the Janssen COVID-19 vaccine builds on the global contributions we have made with both our anaesthetics portfolio and dexamethasone supply. We are particularly proud that this vaccine manufacture is taking place in Africa. We hope that our success will inspire and give confidence to others to further invest in our continent. We have set ourselves a further target to become the pandemic solution for Africa. Security of supply for Africans is best achieved through African facilities. Aspen intends to assist with this goal by targeting further enhancement of capacities on the existing sterile footprint to ensure that we have the capabilities to give one liquid dose of vaccine per African person.” “Finally, with all the capacities and investments, this could not have been achieved without the dedication, commitment and passion of the Aspen and Johnson & Johnson technical teams. To each and every one of you, we at Aspen, in fact every citizen of our continent and millions more across the globe owe you a massive debt of gratitude. You are our heroes. Thank you, Nkosi sikelel’ iAfrika.” Premier Oscar Mabuyane said, “The commitment for this investment was made at the Investment Conference initiated by President Cyril Ramaphosa in 2018, where Aspen announced plans to invest 3.4 billion in our province to manufacture sterile anaesthetics, a niche and high tech manufacturing capability that presents both domestic and export opportunities. We view their investment as the fruits of President Ramaphosa’s leadership and the confidence of social partners to the direction he is leading the country to.” “At that time Aspen made

“Our Aspen philosophy has always been to give purpose to life. This is best achieved by contributing meaningfully to others. Aspen has defined itself and continues to define itself as a company that serves humanity, particularly the most vulnerable amongst us. It was over a decade ago that we made a special announcement on a prior pandemic. Aspen had achieved a global first. The first tentatively approved FDA generic ARV. As a result, this site became the backbone of our country’s roll-out of ARVs, making product for millions of our patients monthly and saving so many lives from that pandemic. Patients we continue to support to this day. Today we are proud to share with you our contribution to the COVID pandemic. Aspen has invested in excess of R3.0 billion at this sterile manufacturing site, the single largest investment in the pharmaceutical industry in South Africa. The new sterile facility contains high-technology, state of the art pharmaceutical equipment and systems that will be used to manufacture advanced sterile medicines, including vaccines.   These investments demonstrate Aspen’s ongoing and enduring commitment to South Africa and the continent. With roots firmly embedded in African soil, a continent which carries a disproportionately high disease burden, the investment in advanced pharmaceutical technology enables Aspen to continue to contribute to improved access to treatment, respond to public health emergencies and create significant economic, export and job creation opportunities.  This facility will enable Aspen to manufacture multiple and complex sterile products, such as vaccines and Aspen’s global anaesthetics products. It will also ensure quality and security of both domestic and international supply.  As SA and the world grapples with the management of the COVID pandemic, it will also meaningfully contribute to the management of this pandemic. Through the collaboration announced between Aspen and Johnson & Johnson, Aspen is the only manufacturing site on the African continent and in the southern hemisphere selected by Johnson & Johnson to compound, fill, finish and package the COVID-19 vaccine. We are very proud and grateful to have the opportunity to partner with one of the world’s largest and most technologically advanced healthcare companies who has committed to ensuring equitable access to COVID-19 vaccines. This they have demonstrated through their actions and was fundamental in our own considerations of whom to partner. The Aspen and Johnson & Johnson project teams responsible for the technical transfer process at new sterile facility, worked tireless ensuring collaboration in keeping to the ambitious goals and even beating timelines.  During this time, the Aspen project team have strengthened their technical competencies, complementing the capabilities of these highly skilled Aspen employees and enhancing a knowledge base in South Africa that will contribute to further solving future public challenges.  The majority of the vaccines manufactured at this facility in 2021 will be supplied to South Africa and the member states of the African Union. The South African government has agreement with Johnson & Johnson, to deliver more than 30 million doses of the Janssen vaccine to South Africans, with the first deliveries being made in April 2021. The African Union will receive 400 million doses. This is a watershed moment for Aspen as we continue to implement our strategic vision of delivering quality, affordable medicines using high technology pharmaceutical equipment that contribute to improved health outcomes.  This vision has come with much sacrifice and perseverance. However, we have been rewarded through endorsement of the relevance of our product portfolio and capital investments in our manufacturing facilities. The manufacture of the Janssen COVID-19 vaccine builds on the global contributions we have made to COVID through sustained supply of both our anaesthetic portfolio and dexamethasone. We are particularly proud that this vaccine manufacture is taking place in Africa. Our sterile capacity is a big step forward to ensuring that Africa has both the capacity and capabilities to reduce its reliance on other countries in addressing the healthcare priorities on the continent. We hope that our success will inspire and give confidence to others to further invest in our continent.   At Aspen, we have set ourselves a further target to become the pandemic solution for Africa. Security of supply for Africans is best achieved through African facilities.  Aspen intends to assist with this goal by targeting further enhancement of capacities on the existing sterile footprint to ensure that we have the capabilities to give one liquid dose of vaccine per African person. A special thank you, to the President, SAHPRA and the Ministers of Health, Trade Industry and Competition and their departments for their unwavering support and commitment and in assisting us, by making this journey as seamless as possible. Finally, with all the capacities and investments, this could not have been achieved without the dedication, commitment and passion of the Aspen and Johnson & Johnson technical teams.  To each and every one of you, we at Aspen, in fact every citizen of our continent and millions more across the globe owe you a massive debt of gratitude. You are our Heroes  Thank you, Nkosi sikelel’ iAfrika.” 

Durban, South Africa – Aspen is pleased to announce that one of its wholly-owned South African subsidiaries, Pharmacare Limited (which trades as “Aspen Pharmacare”), has entered into a preliminary agreement with Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica NV, two of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S. The vaccine candidate is currently undergoing clinical trials. Aspen Pharmacare will perform formulation, filling and secondary packaging of the vaccine for supply to Johnson & Johnson. This agreement is still subject to the successful completion of the relevant technology transfer activities and finalisation of certain commercial manufacturing terms.  Aspen Pharmacare has agreed to provide the necessary capacity required for the manufacture of Johnson & Johnson’s COVID-19 vaccine candidate at its existing sterile facility in Port Elizabeth, South Africa. Aspen has invested in excess of R3 billion in the facility together with the high technology equipment and systems that will be used to manufacture state-of-the-art sterile drugs and vaccines, packaged into vials, ampoules and pre-filled syringes. The production area where it is intended that the vaccine candidates will be manufactured has capacity to produce more than 300 million doses per annum. The facility has accreditation from a range of international regulatory authorities and provides lifesaving medicines to both the domestic and international markets. It was part of the first flagship investments announced at the President’s inaugural South African Investment conference. Stephen Saad, Aspen Group Chief Executive said “We have invested globally in our sterile capability and are determined to play a role in the manufacture of vaccines to add to our proud track record of making contributions to humanity in times of global pandemics. This has included, inter alia, being a leading global supplier for antiretrovirals for the treatment of HIV/AIDS, multi-drug-resistant-TB products and COVID-19-related treatments such as anaesthetics and dexamethasone. We have been selected as a vaccine partner by Johnson & Johnson and this project will receive priority focus. We are particularly pleased to be given the opportunity of providing assistance for patients in need across the world from our South African base.”